Matricelf Ltd is an Israel-based company engaged in the biotechnology sector. The Company operates in the field of tissue engineering and regenerative medicine. The Firm develops a platform for autologous 3D printing of neutral human matrix, cells, tissues and organs implants. The implants are manufactured using cellular components originated from the patients themselves, to reduce potential immune response. The Company focuses on the treatment of spinal cord injury (SCI), but is also involved in developing treatment for additional medical conditions, including: Myocardial Infarction (MI), Parkinsonâ€™s disease and Age-related Macular Degeneration (AMD). Matricelf Ltd is a spin-out company from Tel Aviv University.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	76.62M 25.35M 22.23M 20.59M 18.94M 35.83M 2.43B 36.53M 245M 96.25M 1.19B 95.17M 93.09M 4.11B	P/E 2024	-3.74x	P/E 2025	-3.65x
Enterprise Value	56.48M 18.68M 16.39M 15.18M 13.96M 26.41M 1.79B 26.93M 181M 70.95M 878M 70.16M 68.62M 3.03B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	77.85%	Yield 2024 *	-	Yield 2025	-

07-09	Matricelf Ltd. Receives Approval to Begin Patient Identification and Blood Collection for Planned First-In-Human Spinal Cord Injury Study	CI
06-22	Matricelf Initiates Ind Enabling Efficacy Study for Engineered Human Neural Tissue Implant in Chronic Spinal Cord Injury	CI
06-17	Matricelf Completes GLP Safety Study for Engineered Neural Tissue Implant	CI
03-30	Matricelf Ltd. Enters into Collaborative Research Agreement with CiRA Foundation	CI
03-24	Matricelf Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-24	Matricelf and Sheba Medical Center Enter Strategic Collaboration to Advance First in Human Clinical Program in Spinal Cord Injury	CI
03-24	Matricelf Ltd Auditor Raises 'Going Concern' Doubt	CI
03-04	Matricelf Ltd. Reports Positive RNA Sequencing Results Demonstrating Promising Safety Profile Of Its Personalized Spinal Cord Implant	CI
03-03	Matricelf Ltd. Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy	CI
03-03	Matricelf Ltd. (Tase Mtlf) signs MoU to establish subsidiary for commercialization of Parkinson's disease therapy	RE
02-27	Matricelf Ltd Appoints Ron Mayron as Active Chairman of the Board of Directors	CI
03/08/25	Matricelf Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI
11/03/25	Cellino and Matricelf Announce Global Collaboration to Scale Personalized Spinal Cord Injury Treatments	CI

07-09	Matricelf Continues Clinical Execution with Patient Enrollment Preparation Following GLP Safety Success and GMP Manufacturing Milestones	PR
06-23	Matricelf Initiates IND Enabling Efficacy Study Following Positive Preclinical Results in Spinal Cord Injury	AQ
03-03	Matricelf Ltd. (TASE: MTLF) Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy	PR
03-02	Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board	AQ
02-27	Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board	PR

Manager	Title	Age	Since
Asaf Toker CEO	Chief Executive Officer	53	01/06/2019
Tal Dvir CTO	Chief Tech/Sci/R&D Officer	51	01/06/2019
Alon Sinai COO	Chief Operating Officer	58	01/07/2019

Director	Title	Age	Since
Alon Sinai BRD	Director/Board Member	58	01/07/2019
Tal Dvir BRD	Director/Board Member	51	01/06/2019
Stanley Hirsch BRD	Director/Board Member	68	27/07/2022

Matricelf Ltd Stock TEL AVIV STOCK EXCHANGE

Stocks

MTLF

IL0011767915

Biotechnology & Medical Research

Valuation: Matricelf Ltd

Latest news : Matricelf Ltd

Press Releases: Matricelf Ltd

Quotes and Performance

Managers and Directors: Matricelf Ltd

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MATRICELF LTD	+4.20%	-4.47%	-	-	25.48M
LONZA GROUP AG	+0.44%	+1.41%	+4.25%	+10.81%	50.73B
REVOLUTION MEDICINES, INC.	-2.86%	-4.37%	+373.52%	+584.85%	39.73B
IQVIA HOLDINGS INC.	+1.05%	+1.84%	+30.99%	-4.49%	34.69B
BEONE MEDICINES AG	+1.60%	-1.91%	+20.39%	+53.18%	33.21B
CELLTRION, INC.	-0.06%	-4.63%	+2.94%	+31.65%	26.76B
ASCENDIS PHARMA A/S	-2.11%	-1.16%	-	-	16.8B
MEDPACE HOLDINGS, INC.	-0.85%	-5.65%	+66.43%	+121.77%	15.37B
EUROFINS SCIENTIFIC SE	+0.78%	+1.16%	+15.53%	+17.32%	13.78B
ICON PUBLIC LIMITED COMPANY	-0.11%	-2.23%	+11.78%	-32.88%	12.85B
Average	+0.21%	-0.98%	+65.73%	+97.78%	27.1B
Weighted average by Cap.	-0.21%	-0.38%	+80.46%	+122.98%

	2024	2025
Net sales	-	-
Net income	-15.58M -5.15M -4.52M -4.19M -3.85M -7.29M -493M -7.43M -49.9M -19.57M -242M -19.35M -18.93M -837M	-27.82M -9.2M -8.07M -7.48M -6.88M -13.01M -881M -13.26M -89.1M -34.95M -433M -34.56M -33.8M -1.49B
Net Debt	-10.68M -3.53M -3.1M -2.87M -2.64M -4.99M -338M -5.09M -34.21M -13.42M -166M -13.27M -12.98M -573M	-20.14M -6.66M -5.84M -5.41M -4.98M -9.42M -638M -9.6M -64.5M -25.3M -313M -25.02M -24.47M -1.08B